Identifying blood markers for Alzheimer's disease
Blood DNA Methylation Biomarkers of Alzheimer's Disease
['FUNDING_R01'] · UNIVERSITY OF WISCONSIN-MADISON · NIH-10828781
This study is looking at how changes in DNA from blood samples might help doctors find out if someone has late-onset Alzheimer's disease, making it easier to diagnose and understand the condition.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF WISCONSIN-MADISON (nih funded) |
| Locations | 1 site (MADISON, UNITED STATES) |
| Trial ID | NIH-10828781 on ClinicalTrials.gov |
What this research studies
This research investigates how DNA methylation patterns in blood can help identify and diagnose late-onset Alzheimer's disease. By analyzing blood samples, the study aims to discover specific genetic markers that differentiate between individuals with and without the disease. The approach utilizes advanced techniques to examine changes in DNA methylation, which may provide insights into the biological processes underlying Alzheimer's. This could lead to more accessible and accurate diagnostic methods for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 21 and older, particularly those who may be experiencing symptoms of Alzheimer's or have a family history of the disease.
Not a fit: Patients who are younger than 21 or do not have any risk factors or symptoms related to Alzheimer's disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to earlier and more reliable diagnosis of Alzheimer's disease through simple blood tests.
How similar studies have performed: Previous studies have shown promise in using DNA methylation as biomarkers for various diseases, suggesting that this approach may also be effective for Alzheimer's disease.
Where this research is happening
MADISON, UNITED STATES
- UNIVERSITY OF WISCONSIN-MADISON — MADISON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ALISCH, REID SPENCER — UNIVERSITY OF WISCONSIN-MADISON
- Study coordinator: ALISCH, REID SPENCER
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.